2,131
Views
51
CrossRef citations to date
0
Altmetric
Editorial

Targeting RNA polymerase I transcription and the nucleolus for cancer therapy

, &
Pages 873-878 | Published online: 17 Jul 2013

Bibliography

  • Hannan KM, Sanij E, Rothblum LI, et al. Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta 2013;342-60
  • Derenzini M, Montanaro L, Trere D. What the nucleolus says to a tumour pathologist. Histopathology 2009;753-62
  • Andersen JS, Lyon CE, Fox AH, et al. Directed proteomic analysis of the human nucleolus. Curr Biol 2002;1-11
  • Olson MO. Sensing cellular stress: another new function for the nucleolus? Sci STKE 2004;2004(224):pe10
  • Boisvert FM, van Koningsbruggen S, Navascues J, et al. The multifunctional nucleolus. Nat Rev Mol Cell Biol 2007;574-85
  • Boulon S, Westman BJ, Hutten S, et al. The nucleolus under stress. Mol Cell 2010;216-27
  • Ruggero D. Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling. Sci Signal 2012;5(241):pe38
  • Burger K, Muhl B, Harasim T, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 2010;12416-25
  • Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 2010;131-56
  • Bywater MJ, Pearson RB, McArthur GA, et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer 2013;299-314
  • Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 2011;1418-30
  • Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012;51-65
  • Tovar C, Graves B, Packman K, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013;2587-97
  • Ray-Coquard I, Blay YJ, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;1133-40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.